Kulkarni, Tanmay A.
Bade, Aditya N.
Sillman, Brady
Shetty, Bhagya Laxmi Dyavar
Wojtkiewicz, Melinda S.
Gautam, Nagsen
Hilaire, James R.
Sravanam, Sruthi
Szlachetka, Adam
Lamberty, Benjamin G.
Morsey, Brenda M.
Fox, Howard S. http://orcid.org/0000-0003-2032-374X
Alnouti, Yazen
McMillan, JoEllyn M.
Mosley, R. Lee
Meza, Jane
Domanico, Paul L.
Yue, Tai-Yuen
Moore, Gary
Edagwa, Benson J. http://orcid.org/0000-0003-1484-9331
Gendelman, Howard E. http://orcid.org/0000-0002-7831-0370
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P01MH64570, P01MH64570, P01MH64570)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P01DA028555, P01DA028555, P01DA028555)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI145542)
U.S. Department of Health & Human Services | NIH | Office of AIDS Research (R01AI145542)
Article History
Received: 12 December 2019
Accepted: 31 March 2020
First Online: 27 April 2020
Competing interests
: B.J.E. and H.E.G. are named inventors on patents that cover the medicinal and polymer chemistry technologies employed in this article that encompass the synthesis of long-acting cabotegravir prodrugs and formulation manufacturing. H.E.G. is the Interim Director of the Nebraska Nanomedicine Production Plant, a good manufacturing programme facility. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design, data acquisition, analyses and interpretation, and writing of the manuscript. No other entities provided funds for the work. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.